Abbreviations BBB = blood-brain barrier, CNS = central nervous system, CSF = cerebrospinal fluid, GBCA = gadolinium-based contrast agent, ICP-MS = inductively coupled plasma mass spectrometry, NSF = nephrogenic systemic fibrosis
S
ince initial regulatory approval, over 450 million doses of gadolinium-based contrast agents (GBCAs) have been administered worldwide (1) . The historic safety profile of GBCA use has been highly favorable, with very low rates of immediate adverse side effects when compared with other pharmaceuticals, including iodinated contrast agents (2) (3) (4) . GBCA use in patients with severely compromised renal function has been associated with development of the rare condition nephrogenic systemic fibrosis (NSF), in which fibrotic changes may be seen in many tissues, predominately skin, and muscle contractures may occur (5) (6) (7) (8) (9) . Fortunately, rapid changes in clinical practice in the use of GBCAs within the renally impaired population have essentially eradicated this clinical entity.
At the time of initial regulatory approval in 1988, it was widely thought that the gadolinium ion remained in the chelated state after intravenous administration of a GBCA and that it was rapidly excreted. However, scientific evidence has been mounting that traces of gadolinium remain in the bone, brain, and other organs in patients with normal renal function (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The extent of tissue retention (defined by our writing group as both short term [beyond 24 hours] and long term [.1 month after exposure]) tends to show an association with cumulative dose. Although tissue retention appears to be highest with linear GBCAs, all agents (linear and macrocyclic) demonstrate some degree of tissue retention of gadolinium in some form, and existing data suggest there may be intraclass variability in this retention (17, (22) (23) (24) (25) . The causal relationship between GBCA exposure, retention, and symptoms remains unclear due to inconsistencies in the timing of symptom onset relative to GBCA administration, dose thresholds, and heterogeneity in presumed associated symptoms (26) .
Nine GBCAs have been approved for use in the United States, each with unique chemical and physical properties (Table 1, Figure) (27) (28) (29) (30) (31) (32) . However, in the European Union, the linear GBCAs have recently been restricted or removed from the market due to concerns regarding gadolinium retention. This difference may, in part, be reflective of the differences in the regulatory approach across countries, and it also attests to the limitations in the available research on these agents, their biodistribution, and the effect of long-term retention in tissues, highlighting the need for stronger evidence regarding the safety of these agents.
Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short-or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research.
On February 15, 2018 , an international meeting convened by the National Institute of Biomedical Imaging and Bioengineering and cosponsored by the American College of Radiology (ACR), Radiological Society of North America (RSNA), and National Institutes of Health (NIH) was held to discuss current knowledge and knowledge gaps and to identify and prioritize future research initiatives regarding the mechanisms, biological importance, and clinical implications of gadolinium retention. Attendees (Appendix E1 [online]), including an international group of researchers, GBCA manufacturers, and representatives of the Food and Drug Administration, were invited based on their expertise in a diverse set of scientific and clinical disciplines relevant to the study of the chemistry, measurement, clinical manifestations, or health-related effects of retained gadolinium Note.-Half-life (T1/2) is calculated as ln2/k obs . Note that K therm , K cond , k obs and T1/2 data were not obtained in identical testing, are not an exhaustive listing, and can be highly dependent on conditions; thus, they are only order of magnitude comparable. F = female, K cond = conditional stability constant, k obs = rate constants characterizing the acid-catalyzed dissociation of Gd 3+ complexes, K therm = thermodynamic stability constant, M = male, NA = not available. * Withdrawn from the United States market as of the middle of 2018.
† No longer being manufactured.
in human tissues. The meeting focused on gadolinium retention; it did not specifically address acute or allergic-like reactions to contrast material, nor did it cover regulatory issues regarding GBCA use. The purpose of this research roadmap is to highlight important information that is not known and to identify and prioritize needed research to understand the clinical importance of this retention for patients receiving a GBCA.
Chemical Properties and Stabilities of GBCA
• Stability of GBCA chelates is governed by their thermodynamic stability at equilibrium and lability (rate of approach to equilibrium or "kinetic stability"). As a class, macrocyclic GBCAs are less labile (greater kinetic stability) than linear GBCAs, accounting for lower amounts of gadolinium tissue retention.
• Although in vitro measurements of GBCA lability are typically performed in nonphysiologic acidic aqueous solutions, their relative values have been shown to be consistent with the results of bone deposition studies of gadolinium in animal models and humans.
GBCAs can be categorized by the identity of the organic polyaminocarboxylate ligand (linear and macrocyclic agent subclasses), overall charge (ionic vs nonionic), thermodynamic stability (the affinity of the ligand for the gadolinium ion at equilibrium defined by the pH independent thermodynamic stability constant,
, or as adjusted for physiologic pH, by K cond ), lability or kinetic stability (the rate at which GBCAs
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At physiologic pH, macrocyclic GBCA dissociations were undetectable after incubation at 2 weeks in human serum, while all linear GBCAs showed variable degrees of dissociation; this is despite some cases in which thermodynamic constant differences favor linear agents over macrocyclic agents (27, 28, 36, 37) .
Biodistribution
• Biodistribution properties of GBCAs are more heterogeneous and complex in humans than in rodents. In humans, 73%-99% of the GBCA is excreted within 24 hours after administration, whereas in mice, more than 98% of the GBCA is excreted in that time period.
• Biodistribution data of GBCA in humans beyond the first 24 hours suggests the presence of a longer lasting phase of residual excretion from deep compartments, from which gadolinium is slowly eliminated.
• There is a need to better understand in vivo tissue distribution, transformation, trafficking, and excretion of a GBCA in normal individuals and in more vulnerable groups, such as children or adults with comorbidities that might affect biodistribution, such as diabetes, osteoporosis, and renal osteodystrophy.
The short-term biodistribution and clearance of an intravenously administered GBCA have been extensively studied both in animals and in humans (38, 39) (Table 1 ). The general-purpose GBCAs are primarily cleared via glomerular excretion, with approach equilibrium [otherwise known as dechelate; dissociate, defined by a dissociation constant, k obs ; or reach their half-life [T1/2]), protein binding, and relaxivity (Table 1) . At equilibrium, the thermodynamic stability constant, K cond , can be used to calculate the relative concentration of the intact chelated GBCA, unchelated gadolinium, and unchelated ligand. K cond describes the GBCA system at equilibrium in an aqueous solution at physiologic pH. Once GBCA is injected, however, the system is no longer at equilibrium because of the varied competitive microenvironments that exist in vivo.
The system subsequently will reestablish a new equilibrium over a time period defined by the lability of the GBCA at the in vivo conditions. GBCAs also differ in their tissue uptake and intracellular stability. Central to the current safety concern is the imperfect stability of all gadolinium chelates, a consequence of balancing the need for strong kinetically inert GBCA ligand-gadolinium bonding with one kinetically labile H 2 O-Gd bond that is required for effective bulk water proton relaxation-the fundamental basis for contrast enhancement at MRI. Accordingly, all GBCAs exist in chemical equilibrium with free gadolinium and free ligand and are governed by their unique thermodynamic and kinetic properties (Table 1) . Macrocyclic GBCAs are more stable than linear GBCAs, but there are differences among the class members as well.
Dechelated forms of gadolinium in vivo are potentially myriad and include "free" forms that associate with anionic counter ions (eg, OH -, PO 4 3-), forms that associate with negatively charged biopolymers (eg, protein side chains, nucleic acid phosphate ester backbones), and insoluble precipitates (33) . Identification of the form or forms of dechelated gadolinium is critical to understand the biodistribution, potential toxicity, trafficking, long-term stability, and lability of retained gadolinium species. Gadolinium may also be retained long term as an intact GBCA chelate (34, 35) . Stability parameters measured in aqueous solutions in vitro are useful only to the extent that they are predictive of in vivo thermodynamic stability and lability. The thermodynamic stability constants are used to differentiate two subclasses of linear agents, and the dissociation kinetics show that macrocyclic GBCAs are overall less labile (more kinetically inert to dissociation) than are linear GBCAs, owing to the macrocycle-enhanced chemical rigidity and reduced conformational freedom. will gadolinium in bone be mobilized in patients with osteoporosis, renal osteodystrophy, or hyperparathyroidism? Does the immature or treatment-altered blood-brain barrier (BBB) predispose one to gadolinium retention? Are patients who are exposed to higher levels of iron, zinc, manganese, lanthanides, or copper at greater risk for transmetallation effects when exposed to a GBCA (49) (50) (51) (52) (53) (54) ? Will other chronic diseases, such as diabetes, affect the biodistribution of GBCA? Improved noninvasive protocols to measure the biodistribution and elimination of retained gadolinium are needed to provide temporal information to understand GBCA kinetics. Although gadolinium can be detected in the urine for months, or possibly even years, after GBCA administration, age-and sex-defined normative ranges have yet to be prospectively defined. Measurement of serum levels is another potential method with which to monitor gadolinium retention, and it should be studied as a possible monitoring technique (55) . Each agent needs to be studied, not just one agent from each class. Standardization of specimen collection, storage, and measurement needs to be established to ensure uniform reproducible clinical laboratory testing. Even local environmental water supply concentrations of anthropomorphic gadolinium (56) may need to be considered when establishing normal reference ranges for different regional populations.
Speciation
• Limited information is available on the biologically active and potentially toxic chemical forms of retained gadolinium in tissues. These include intact GBCA; soluble GBCA metabolites; one of many possible inorganic insoluble or matrixed entities (eg, hydroxyapatite); solid hydroxides, oxides, phosphonates, carbonates or combinations of insoluble species; or gadolinium bound into macromolecular or macrostructural forms.
• While this information is essential for evaluating potential toxicity of GBCA, it is largely unknown.
• Appropriate studies to identify these chemical species are technically challenging and require the use of an array of techniques.
Speciation analysis seeks to identify the chemical forms and interactions of gadolinium in tissues and is an essential element of absorption, distribution, metabolism, and excretion (or ADME) studies that are, in turn, required for the interpretation of toxicologic and clinical studies (33) . Because unchelated gadolinium ions are considerably more toxic than the gadolinium chelates used in GBCA, the primary focus of speciation is to identify the biologically inactive (presumable gadolinium chelate) versus potentially toxic chemical forms of residual gadolinium within tissues (33, 57 (38, 47) . Several knowledge gaps exist. First, details of in vivo tissue distribution, transformation, trafficking, and excretion are incomplete. Existing biodistribution data are limited by the absence of side-by-side comparisons of all approved GBCAs using standardized animal and human protocols. Second, human biodistribution data are much more limited than animal biodistribution data, and pharmacokinetics in animals differ from those in humans. For example, hepatobiliary excretion of gadobenate dimeglumine is much higher in rat models (about 50%) than in humans (about 5%) (48) . Third, much less is known about the potentially more complex biodistribution of the chronically retained gadolinium fraction, including its chemical form or forms, equilibration, and lability, and its propensity to be slowly cleared over time (44) .
In addition to defining gadolinium distribution patterns and elimination rates in normal populations, it is also critical to define potentially altered dynamics in potentially vulnerable populations. Fetal, infant, and early childhood populations may be uniquely vulnerable due to ongoing growth and development, and these populations have a long life expectancy, during which retained gadolinium may exert a clinically important effect. Identification of events, comorbid conditions, and clinical therapies that may mobilize gadolinium into the serum and affect elimination rates may help identify other potential vulnerable populations. For example, fresh frozen tissue samples saved at autopsy or surgery. Fresh frozen tissue may be more desirable, since the fixation process may alter gadolinium distribution and speciation. The common practice of choosing to study one member of each GBCA subclass (for example, macrocyclic vs linear) ignores the fact that differences between individual GBCAs (Table  1) exist and may affect results of speciation studies, making generalization among classes and subclasses unreliable in the absence of full data sets using all GBCA moieties.
Additional limitations of these studies lie in the technical issues surrounding the instrumentation and methods used in trace metal and GBCA speciation analyses. Highly sensitive speciation analyses generally involve separating gadolinium from tissue, requiring tight control of variables. Current limitations include (a) validation that the methods do not change or favor one chemical form of gadolinium over another; (b) movement of retained gadolinium species among tissue compartments during extractions, causing different gadolinium exposure from that which was present in vivo; (c) imperfections inherent in substituting animal tissues for human tissues; (d) the relative lability of the ligands involved in many biologically relevant forms of dissociated gadolinium, such as gadolinium macromolecules; and (e) gadolinium produced after presumed gadolinium dissociation from GBCA.
To fully understand the in vivo trafficking of GBCAs and their metabolites, a combination of speciation techniques (Appendix E2 [online] ) is needed to accurately determine the chemical speciation of GBCA and gadolinium. All speciation methods require relevant controls, and best practices will depend on combining methods to ameliorate weaknesses and magnify strengths ( Table 2) .
To interpret absorption, distribution, metabolism, and excretion data on the final small percentage of retained GBCA or gadolinium that is not rapidly excreted, human tissue biodistribution analyses are needed. An ideal approach would be to develop a multiorgan tissue biorepository that is not confounded by multiagent GBCA contamination, with reliable patient history data (eg, date or dates of GBCA administration, estimated glomerular filtration rate at each administration, GBCA dose, and specific GBCA used), that could be preserved for future analysis. Such a tissue biorepository would alleviate one of the greatest hurdles in future speciation studies: the dearth of well-characterized human tissue samples from patients exposed to gadolinium. These tissues could be harvested from formalin-fixed or (55) Optical and other properties of lanthanides can be structure dependent
Indirect information hard to validate
Note.-ENDOR = electron nuclear double resonance, EM = electronic microscopy, ESR = electron spin resonance, EXAFS = extended x-ray absorption fine structure, ICP = inductively coupled plasma, MSA = mass spectral analysis, NMR = nuclear magnetic resonance, NMRD = nuclear magnetic relaxation dispersion, XRF = x-ray fluorescence.
Gadolinium Retention 6 radiology.rsna.org n Radiology: Volume 00: Number 0-2018 respective manufacturers and has been reported in the approved product labeling (26, (72) (73) (74) . Tests included evaluations of the general pharmacology, general toxicology (single and repeated doses), organ-specific toxicities, genetic toxicology, reproductive and developmental toxicology, and local tolerance studies. In central nervous system (CNS) safety studies conducted by the Food and Drug Administration for GBCA approval, adverse effects (histologically or behaviorally) were not detected in single-or repeated-dose studies at high GBCA dose multiples and in multiple animal species. However, the standard test batteries may not be sensitive enough to enable detection of rare or subtle effects, highlighting the need for new approaches, such as sensitive animal models, expansion of nonclinical functional testing, and improved assay sensitivities. Furthermore, the patient populations that are potentially more vulnerable to GBCA side-effects have not been fully defined. Maximova et al (54) have shown elevated gadolinium levels in the livers of pediatric patients with concomitant iron overload amenable to chelation therapy with deferoxamine mesylate. It is unknown if other potentially vulnerable populations (eg, fetal, pediatric, pregnant) with higher cell turnover are at greater risk for gadolinium-mediated toxicity. Fetuses and children are also potentially vulnerable because of ongoing CNS development, immature renal function, and active bone formation. GBCA administered to pregnant nonhuman primates resulted in measurable gadolinium concentration in the bone, brain, skin, liver, kidney, or spleen of offspring for at least 7 months (75) . Although gadolinium retention is lower in the brain than in bones or skin, there are concerns about metal toxicity in the brain and developing organs.
Unlike the known acute toxicities of gadolinium and GBCAs, there is less evidence of chronic GBCA-mediated toxicities after intravenous administration in animal models, even when animals are exposed to supradiagnostic doses that exceed clinical doses by one to two orders of magnitude. However, some evidence of harm from retained gadolinium was reported by Khairinisa et al in pregnant BALB/c mice. Prenatal exposure to intravenous gadoterate meglumine or gadodiamide (embryonic days [15] [16] [17] [18] [19] was associated with abnormal behaviors and decreased muscle strength (76) .
The following areas of research are suggested to better understand the potential toxic effects of retained gadolinium: (a) development of animal models (species, prenatal, juvenile, and adults); (b) adoption of uniform study protocols for side-by-side simultaneous comparison of GBCAs; (c) standardization of safety (including CNS safety) and toxicology study protocols (dose, multiple doses, dose timing, dose frequency, observational batteries, timing of evaluations, and assay methods, particularly those for gadolinium levels) that go beyond the recommendations for initial regulatory approval, as established by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (74); (d) characterization of gadolinium retention; (e) development of biomarkers of toxicity; and (f ) standardization of critical assay elements.
exposure of gadolinium to new microenvironments during tissue homogenizations (eg, ones that disrupt cell membranes). The importance of ensuring the benign separation, causing no important change to the tissue or alteration of the gadolinium species extracted, cannot be overemphasized. Analytical methods and controls are imperfect, and multiple complementary methods are recommended to alleviate the weaknesses of individual techniques.
Toxicology
• The acute non-allergic-like toxic effects of gadolinium salts are due to competition with calcium-dependent biologic processes, cytotoxic effects, inducement of cytokine expression, and inhibition of mononuclear phagocytosis. Gadolinium chelates do not show these effects.
• All the general pharmacology, general toxicology (single and repeated doses), organ-specific toxicity, genetic toxicology, reproductive and developmental toxicology, and local tolerance studies expected for any drug have been performed for each GBCA.
• The potential toxicities of the small pool of retained GBCAs, their metabolites, as well as the soluble and insoluble complexes derived from this pool, are largely unknown.
The fate of the small percentage of an administered GBCA that is not rapidly excreted is at the center of current concerns for three reasons. First, gadolinium has no known biologic role in vivo; however, it is known to have adverse biologic effects (5, 49, (58) (59) (60) (61) . Second, gadolinium plays a role in the development of NSF, albeit inconsistently, since not all patients with severely compromised renal function who had multiple exposures to a GBCA developed NSF, and some patients with renal failure developed NSF after only one exposure to a GBCA (5) (6) (7) 62, 63) . Third, some forms of residual gadolinium from GBCAs have long biologic residence times (10, 12) . Thus, the small fraction of the retained GBCA or any of the products of its dissociation might have the potential to lead to chronic toxic effects. The acute toxic effects of gadolinium salts and other rareearth metals have been extensively studied (30, 58, (64) (65) (66) . Acute toxic effects may arise from the ability of gadolinium to interfere with calcium-mediated cellular processes (38, 58, 59) . Gadolinium also has been shown to be a cytotoxic agent and can modulate the immune system via induction of cytokine expression and inhibition of the mononuclear phagocyte system (67, 68) .
Toxicity in gadolinium chelates also has been studied. Although GBCAs are well tolerated when administered intravenously at clinically relevant doses, at much higher experimental doses, well-defined toxic and lethal nonclinical dose thresholds were observed with all GBCAs (69). Additional acute neurotoxic effects (delayed seizures hours after administration) have been observed in canines with an osmotically disrupted BBB (70) . Such effects are attenuated in mammalian species, such as rats, with more primitive brain parenchyma and sulcation (71) .
To satisfy regulatory requirements, the safety and toxicologic potential of each GBCA has been evaluated by the 7 This phenomenon of retained brain gadolinium is not limited to patients with potential BBB disruption and has been seen in decedents with normal brains at the time of autopsy without clinical history of an inflammatory, neoplastic, traumatic, or infectious intracranial history (12) . Intracranial gadolinium retention also has been identified in the pediatric population after exposure to gadodiamide and gadopentetate dimeglumine (11, 25 ).
An animal model of intracranial gadolinium retention revealed substantially higher gadolinium retention in brain tissues after exposure to gadodiamide relative to gadoterate meglumine (24) . In this study, researchers confirmed the superior sensitivity of ICP-MS, as detectable levels of gadolinium after gadoterate meglumine administration at approximately 20 human dose equivalents (0.6 mmol per kilogram of body weight per dose 3 20 doses) were observed by using ICP-MS despite the lack of T1 shortening in the cerebellar roof nuclei. Subsequent studies in a rat model revealed significant inter-and intraclass differences in neural tissue gadolinium retention at 80 human dose equivalents (22) ; at this dose, significant differences in retention, even among macrocyclic agents, were found, and these observations have been confirmed in animal studies by Bussi et al (23) and Gianolio et al (90) . It should be noted that these human dose equivalents are based on animal body surface area. These animal studies variously had multiple GBCA or control injections over a 3.5-7.5-week interval and then underwent imaging assessment and/or measurement of gadolinium 3 days to 5 weeks after the final injection. Longer-term retention data are needed to better understand differences in the biodistribution of different GBCAs.
Other human and animal studies have provided potentially useful preliminary data on the biodistribution of intravenously administered GBCA in the context of an intact BBB. Transmission electron microscopy with energy-dispersive x-ray spectroscopy studies of the ultrastructural distribution of retained gadolinium within neural tissues revealed that the majority was localized to the endothelium of capillaries outside of the BBB while a much smaller fraction of gadolinium-enriched foci either circumvented or directly traversed the BBB and was detected in the neural interstitium and cellular organelles (10) (11) (12) . Animal studies by Jost et al have shown that all GBCAs, regardless of class, enter the cerebrospinal fluid (CSF) from serum, and that neither GBCA structure nor physicochemical properties affect CSF penetration and distribution (91) . These findings parallel clinical observations in delayed GBCA-enhanced MRI examinations in which gadolinium has been indirectly detected in the perivascular spaces and CSF through the effects of T1 shortening (92) . The presence of gadolinium in CSF has been verified in humans undergoing lumbar puncture after gadobutrolenhanced MRI. Gadolinium clearance from CSF roughly approximated first-order kinetics, with detectable levels of gadolinium still present up to 30 days after initial GBCA administration (93) . Despite the identification of retained gadolinium in neural parenchyma using transmission electron microscopy with energy-dispersive x-ray spectroscopy, there
Retention of Gadolinium in CNS Tissues
• Dose-dependent increases in signal intensity in the globus pallidus and dentate nucleus at T1-weighted MRI have been identified in patients receiving a linear GBCA. In a smaller number of studies, researchers have also reported a similar but less pronounced change with macrocyclic GBCAs.
• Autopsy studies using inductively coupled plasma mass spectrometry (ICP-MS) among patients receiving a linear GBCA have shown high T1 signal intensity in the dentate nucleus and globus pallidus is related to the presence of retained gadolinium in these regions.
• ICP-MS studies on brain tissue obtained at autopsy in patients receiving macrocyclic GBCA are limited at this time, but the results confirm the presence of retained gadolinium in these areas.
• Animal studies with ICP-MS and transmission electron microscopy have shown focal retention of linear and macrocyclic GBCAs in brain tissues.
• The identification of compounds associated with retained gadolinium that are visible at MRI, as well as the compounds that are not visible at MRI, represents an important knowledge gap.
In 2014, Kanda and colleagues (21) hypothesized the existence of intracranial gadolinium retention based on the observation of progressive unenhanced T1 signal intensity increases in the dentate and globus pallidus at clinical MRI in human subjects who received gadopentetate dimeglumine or gadodiamide. Subsequent studies have enabled independent confirmation of progressive T1 signal shortening after intravenous administration of linear GBCAs (13) (14) (15) (77) (78) (79) . However, there is disagreement in the scientific literature regarding the presence of this signal phenomenon after administration of the macrocyclic GBCA. While most reports have not shown dose-dependent changes in T1 signal with macrocyclic GBCA exposure (15, 77, (79) (80) (81) (82) (83) , a weak T1 signal change associated with macrocyclic GBCA has been reported (84) (85) (86) (87) (88) . The reasons for these disparate findings are unclear, and they may be related to heterogeneity among macrocyclic agents, differences in MRI examination and assessment parameters, heterogeneity in patient factors, inaccuracies in patient data collection, or differences in study methods. In addition, it is unclear what gadolinium-containing species is producing T1 shortening, leading to the possibility that only the MRI visible forms are being selectively detected. In 2015, two independent human autopsy studies using ICP-MS showed the presence of retained gadolinium in the dentate and globus pallidus (10, 89) . Subsequent study of human brain tissues demonstrated measurable gadolinium after single-dose intravenous administration of both linear and macrocyclic agents (17) . However, significantly less gadolinium retention was observed after macrocyclic agent exposure when compared with linear agent exposure; this finding is in keeping with the greater overall stability of macrocyclic chelates. Although the greatest gadolinium concentrations have been measured in the regions with greatest T1 shortening effects (dentate nucleus and globus pallidus), ICP-MS analysis has served to confirm more widespread low-level retention in all brain parenchyma (89).
radiology.rsna.org n Radiology: Volume 00: Number 0-2018 exposure shows undetectable or one to two orders of magnitude lower T1 shortening effects when compared with linear GBCA administration, despite ICP-MS data that some long-term CNS gadolinium accumulation occurs with all GBCAs. This discrepancy may well be a manifestation of the inferior detection sensitivity of MRI signal analysis relative to ICP-MS; however, the chemical form of retained gadolinium also may differ between linear and macrocyclic agents. Specifically, T1 shortening effects of retained species associated with macrocyclic agents may be weaker than those from linear GBCA exposure (33, 90) . In vitro chromatographic data of cellular homogenates appear to support this hypothesis, as retained gadolinium after intravenous administration of linear agents was associated with a greater fraction of insoluble and macromolecule-bound gadolinium complexes than what was observed with macrocyclic agent administration (36, 90) . However, process controls suggest that the processes used to assess in vitro chromatographic data of cellular homogenates exposed extracellular gadolinium and GBCA to intracellular proteins, which adds uncertainty to the quantitative results. (g) A final uncertainty is the relevance of ultrastructural and histopathologic studies to potential gadolinium mediated toxicity. The absence of a priori knowledge of the chronic effects of retained gadolinium makes it difficult to know if investigators are assessing the right location.
Retention of Gadolinium in Non-CNS Tissues
• Gadolinium retention in the skin, bone, liver, and other organs has been reported. Bone tissues are thought to be one of the primary reservoirs of gadolinium in the body, as gadolinium is actively incorporated by osteoblasts into the bone matrix and can replace calcium in hydroxyapatite formation.
• Some fraction of chronically retained tissue gadolinium may be labile or bioconvertable to a more soluble form of gadolinium.
• Although free gadolinium salts have been shown to be profoundly toxic to many tissue types, little is known about the toxicities of retained gadolinium species, including which tissues may be more sensitive to these toxicities.
Biodistribution studies demonstrate gadolinium retention in the skin for months to 1 year after intravenous GBCA administration (47) . In 1995, Tweedle et al showed that lability of the GBCA was predictive of the extent of gadolinium detected in tissues at 14 days, suggesting a possible role for dechelation in long-term tissue retention (38) . Pietsch et al (47) support this GBCA stability and retention hypothesis by showing an inverse relationship between GBCA thermodynamic stability and GBCA lability in gadolinium skin retention. However, stability alone is not entirely predictive of retention, as the propensity for retention in each organ can differ between GBCAs, as demonstrated in a study of gadolinium retention in rats, in which gadodiamide had its highest retention concentration in skin and gadopentetate dimeglumine had its highest retention concentrations in bone (97) . Skin lesions associated with GBCA administration have been reported both in animal models and in human subjects is no explicit evidence of gadolinium directly transgressing the intact BBB. The mechanisms of transit across the blood-CSF barrier, retention in neural tissues, potential role of concomitant radiation or chemotherapy (94, 95) , and clearance via the glymphatic tissues are currently poorly understood.
No convincing evidence of chronic toxicity arising from retained gadolinium in neural tissues introduced via intravenous administration has been reported. Studies of human brain tissues and animal studies have consistently failed to demonstrate histopathologic evidence of injury to neurons or the neural interstitium (10, 12, 22, 89, 96, 97) .
Although there is now data that all GBCAs leave trace amounts of residual gadolinium in brain tissues after intravenous GBCA administration, substantial limitations of existing data include the following: (a) Small sample sizes and focus on specific patient populations make it difficult to generalize results to the larger and less chronically ill general population. Importantly, T1 signal intensity changes are less sensitive than techniques used in tissue analysis. (b) Inconsistent experimental designs with heterogeneity in clinical and animal study methods limiting the comparability of results between studies. In T1 signal analyses, standardization in the pulse sequence parameters and techniques to analyze and report imaging findings is lacking. In tissue studies, standardization is lacking in the quality controls in analytical instrumentation, reference ranges, and dissection techniques. (c) Limited human data hinder comparisons between GBCAs. Most human data have been from single center studies with only one or two specific GBCAs in local clinical practice, thereby limiting the comparability of results among GBCAs. (d) Generalizability of animal model results to humans is not established. Physiologic and structural differences between humans and animal models may limit the usefulness of animal data. For example, rats are commonly used in toxicology studies, but the lack of substantial sulcation/gyration of the rat brain compared with that in humans limits the generalizability of behavioral and neurologic assessments of these animals to humans, and different species may have differing tolerance to retained gadolinium. In addition, there is abundant evidence that the amount of measured gadolinium in human brain tissue is substantially higher when normalized per unit dose and body surface area when compared with that in rodent models. The mechanisms to account for these differences are unclear, as is whether current human-toanimal dosing conversions are sufficiently accurate to simulate acute or chronic human exposure to retained gadolinium. (e) We do not yet fully understand the mechanism of gadolinium retention and washout, nor do we understand the reason for disproportional focal accumulation, such as in the globus pallidus and dentate nucleus. Why gadolinium preferentially localizes to these areas of the brain is unclear, but one untested hypothesis is that gadolinium is being sequestered by the same cellular mechanisms that sequester calcium in the same neuroanatomic regions due to the similar charge and size between gadolinium and calcium. Further, there is a strong correlation between sites of iron and gadolinium retention, potentially due to interactions with iron-containing molecules. (f) We also do not understand the discrepancy between T1 signal changes and mass spectrometry results. In general, retained gadolinium from macrocyclic agent 9 Clinical Importance of Gadolinium Retention in Humans
• At this time, the clinical importance of gadolinium retention in humans is unknown.
• At the time of this writing, 139 patients with normal or nearnormal renal function have been reported to the Food and Drug Administration with non-allergic-like symptoms (eg, joint pain, fatigue, and cognitive changes) and signs they have attributed to GBCA administration; there is insufficient data to confirm that these clinical manifestations are the result of GBCA exposure or gadolinium retention.
• It may be possible to evaluate the clinical importance of gadolinium retention in humans by analyzing pre-existing electronic medical records, databases from prospectively accrued trials, or registries that incorporate neurocognitive studies and patientreported symptoms.
The central clinical question with respect to gadolinium retention is whether it has clinically meaningful effects and, if so, whether those effects are common or rare or if they are subtle or serious but not recognized. The risks of GBCA administration resulting in NSF or an acute nuisance or life-threatening allergic-like reaction are known and can be addressed with existing risk-mitigation protocols. These quantifiable adverse events can be balanced against the potential benefits of making a diagnosis, excluding a diagnosis, or monitoring a disease when a GBCA-enhanced examination is considered. This riskbenefit assessment is common for all diagnostic procedures and allows the informed provider and patient to make a sound decision regarding the need for a contrast-enhanced examination. Gadolinium retention complicates this assessment. Although it is known to occur, its clinical importance remains undefined. Relative to the hundreds of millions of doses of GBCA that have been administered in the United States over three decades, there are published reports of only 139 patients, all with normal or minimally impaired renal function, who have reported non-allergic-like effects that they associated with GBCA exposure, with onset often shortly after one dose (105, 106) . Some of the patients reported joint and cognitive symptoms that overlap with some symptoms of patients with NSF. A small subset (n = 25) of these patients underwent experimental chelation therapy, with a subsequent increased level of gadolinium in the urine, transient worsening of symptoms in 11 patients, and overall symptom improvement in 13 (107); however, there were no control subjects. There are no controlled prospective study data to confirm a causal link between gadolinium retention and symptoms, nor has chelation therapy been performed in a blinded or randomized fashion.
Forslin et al (108) performed a retrospective 18-year longitudinal cohort study in 23 subjects with multiple sclerosis exposed to GBCA and 23 healthy age-and sex-matched control subjects who underwent unenhanced MRI. The results showed that increased signal intensity in the dentate nucleus in the patients with multiple sclerosis was associated with lower verbal fluency scores at neuropsychological testing. The presence of neurologic disease, however, is a major confounder. Ray et al (109) analyzed universal health care databases for the province (55, 97, 98) . A correlation between gadolinium skin concentration and the presence of skin lesions has been suggested (7, 35, 55, 99) . Animal data suggest that skin lesions are an inflammatory response to acute GBCA exposure rather than to chronic gadolinium retention (67) . While most skin lesions observed in nonclinical studies have been associated with supradiagnostic gadodiamide exposure, subtle changes in rodent skin occurred, even with more stable GBCAs (100). Both insoluble and soluble forms of gadolinium, including intact GBCA molecules, are retained in the skin of patients with NSF, further complicating our ability to identify what form or forms may be potentially toxic (35, 50, 63, 101) .
Skin is the human tissue in which gadolinium retention has been most studied because of efforts to understand the mechanisms underlying NSF. In other human organs and tissues, gadolinium retention is less well-characterized when compared with animal models, but it has been reported in many other tissues, including the musculoskeletal system (muscles, tendons, and bone), nerves, blood vessels, and selected visceral organs in patients with and those without NSF (17, 102) . Bone tissues are thought to be one of the primary reservoirs of gadolinium in the body, as gadolinium is actively incorporated by osteoblasts into the bone matrix and can replace calcium in hydroxyapatite formation (50) . Human autopsy studies have shown trace amounts of gadolinium in bone (and skin) retained up to 2 years after GBCA administration. Gadolinium levels in bone were much higher than those in skin or brain (17) . Toxicities may manifest differently between tissues; for example, the brain heals by gliosis, and the skin heals by fibrosis.
Recent nonclinical studies suggest that a certain fraction of chronically retained tissue gadolinium may be labile or bioconvertable to a more soluble form of gadolinium. Smith et al (96) , Frenzel et al (103) , and Behzadi et al (104) have shown a slow washout of detectable tissue gadolinium over many months after gadodiamide or gadobutrol exposure; this washout appears to be more robust with macrocyclic agents, where the amount of retained gadolinium 52 weeks after supradiagnostic exposure was only 13% of the amount retained, as measured with ICP-MS at 5 weeks (103) . In comparison, a more attenuated washout phenomenon was observed after gadodiamide administration, with 50% of the initially measured amount retained at 1 week still present 20 weeks after administration (96) . Longer-term washout data are needed at common time points to permit comparability between agents and classes.
Despite considerable accumulated knowledge on gadolinium retention in non-CNS tissues, several knowledge gaps remain. First, although free gadolinium salts have been shown to be profoundly toxic to many tissue types, little is known about the toxicities of retained gadolinium species, including which tissues may be more sensitive to these toxicities. Second, it is unclear if retained gadolinium poses a long-term risk in patients exposed to large GBCA doses early in life and what, if any, physiologic triggers may liberate or convert this retained pool into a more biologically active chemical form.
radiology.rsna.org n Radiology: Volume 00: Number 0-2018 will be very small. It is important to establish an acceptable risk tolerance with respect to gadolinium retention so that future studies can be appropriately powered to enable detection of rare or subtle adverse effects, recognizing it is not possible to scientifically prove the absence of harm. The specific signs, symptoms, and diseases to investigate are unclear. Rare at-risk genetic variants and unusual concomitant medical conditions will need to be considered. Early studies have focused on neurocognitive effects due to the retention of gadolinium observed in the deep brain nuclei, but gadolinium retention occurs throughout the body in multiple tissues and organs at much higher concentrations than those in brain tissues. Consultation with toxicologists and interrogation of large population-based exploratory studies (eg, claims-based and "big data"), possibly using artificial intelligence methods, may be helpful to generate hypotheses for future directed study (113) .
Studies and experience have established a strong safety profile for all Food and Drug Administration-approved commercially available GBCAs. Since any obvious clinical manifestations of retained gadolinium have escaped clinical detection in the vast majority of exposed patients, the search for effects should focus on two main types of adverse events: (a) common and small (eg, a global minute decrement in cognitive performance) or (b) rare and severe (eg, debilitating pain). Appropriate power will be critical in any study design, particularly if more than one GBCA is studied. In recognition of this fact, funding agencies and industry need to work cooperatively to study this issue without corporate bias. Study designs should include as many GBCAs as are feasible. Since GBCAs within a class (eg, macrocyclic vs linear, ionic vs nonionic) may behave differently than others within the same class, GBCAs should be studied and reported as a class and individually. Since anecdotal and uncontrolled studies are unlikely to yield results that can withstand scientific scrutiny, suitable controls are necessary and should consider potentially confounding factors, such as pre-existing clinical and laboratory parameters, time from last GBCA administration (due to slow excretion over months), and dosing schedule.
Researchers are encouraged to identify and use pre-existing large databases from prospectively accrued trials or natural history studies that did not investigate a neurologic disease (ie, to avoid confounding) but to include neurocognitive testing as an end point. Phase IV studies analyzing potential subtle, persistent, or delayed manifestations will need to be appropriately powered and should be targeted to plausible symptoms. Registries that incorporate sophisticated neurocognitive testing can be created and informed by retrospective exposure histories, which will minimize the time demands of the study (compared with prospective monitoring of exposure-naïve subjects) but will be limited by recall bias and incomplete histories. Registries also could be considered that avoid expensive neurocognitive testing and instead solicit open-ended self-reported symptoms from exposed and unexposed subjects. Patients who believe they have been adversely affected by gadolinium retention should be approached for possible inclusion in prospective blinded randomized trials of chelation therapy or other future treatment options; a cross-over design might mitigate the stigma of placebo. Given the potential of Ontario, Canada, to identify all births of more than 20 weeks gestation from 2003 to 2015. Among the 1 424 105 deliveries, 397 women underwent GBCA-enhanced MRI during pregnancy. When compared with a cohort of women who did not undergo MRI during pregnancy (n = 1 418 451), in utero contrast-enhanced MRI was associated with an increased risk of a heterogeneous array of rheumatologic, inflammatory, and infiltrative skin conditions, as well as an increased adjusted risk of stillbirth and neonatal death (n = 7 in the GBCA group). However, the study was limited by lack of control for the reason GBCA was administered during pregnancy. This information is crucial, since the underlying condition requiring MRI could have affected pregnancy outcome.
Quattrocchi et al (110) studied resting-state functional imaging of the dentate nuclei and basal ganglia among human patients with inflammatory bowel disease and did not find evidence of brain functional changes in patients with visible T1 hyperintensity after exposure to gadodiamide; however, they did identify subtle nonsignificant changes in functional activation that may merit further investigation.
In 2016, Burke et al (106) published observations from 50 patients who previously underwent GBCA-enhanced (both linear and macrocyclic) MRI and who attributed symptoms to GBCA exposure. The symptoms (ie, chronic pain, fatigue, dermal changes, musculoskeletal disturbances, cognitive and visual impairment) manifested within 1 month of exposure, with over 50% of onset within the first 24 hours. All reported persistence of symptoms 2 months to 6 years after GBCA exposure. An association between these symptoms and GBCA exposure was posited by the authors, who termed the constellation of findings "gadolinium deposition disease" (111) . However, due to limited data and no control group or blinding, the causative association between these symptoms and chronically retained gadolinium remains speculative. If these symptoms are indeed due to gadolinium, they might be an idiosyncratic acute or semiacute process requiring only exposure to , not long-term retention of gadolinium. If clinical manifestations from gadolinium retention exist, it is unknown if they vary by GBCA type or GBCA class, if they are dose dependent, if they are acute or delayed in onset, or whether any dose-dependent threshold is crossed in clinical use.
At the September 2017 Food and Drug Administration Medical Imaging Drugs Advisory Committee (MIDAC) meeting, a presentation on patients reporting symptoms potentially related to GBCA exposure indicated their MRI examinations were performed for a variety of medical conditions. A total of 132 case reports were identified, with various symptoms often centering around pain; most were self-reported and lacked details, such as the specific GBCA product used, the number of GBCA administrations, and the time to onset of symptoms (26) . The MIDAC concluded that no causal relationship between gadolinium retention and patient symptoms could be established at this juncture but that further study was needed (112) .
To date, there is no established risk tolerance threshold for chronic gadolinium retention. If gadolinium retention is associated with clinical harm, the harm is likely rare or occult for the vast majority of exposed patients; thus, the clinical effect size Although gadolinium can be detected in the urine in patients for months, or possibly even years, after GBCA administration, the expected range of gadolinium in urine is not known and needs to be systematically studied. Gadolinium in serum, although considerably lower in concentration than gadolinium in urine, is another potential source for gadolinium monitoring that may be easier to obtain than 24-hour urine concentrations and should also be studied as a possible monitoring technique. Specimen collection, storage, and procedures for avoidance of contamination together with standardized measurement protocols need to be established Number of laboratories currently certified to perform trace metals analysis on human tissues is very limited Can accrue large numbers of patients. Analysis will need to control for the indications for GBCA exposure. Machine learning could be used to identify unexpected symptoms.
May be difficult to incentivize site participation and adequate follow-up. Need to define risk threshold a priori to inform power calculation. Registries that include GBCA-exposed patients using retrospective exposure histories will increase efficiency but decrease accuracy. Registries of GBCA-naïve subjects will be less biased but may take a decade or more to inform the hypothesis. What is the risk benefit of each GBCA in clinical use?
In silico risk benefit model created from the most up-to-date clinical and scientific evidence (retrospective and prospective) regarding the use of GBCAs, incidence of adverse events, and quantification of benefits (clinical utility, indications, etc)
The benefit-risk balance of each GBCA remains largely unknown and requires quantification with well-accepted risk-benefit models. These data will help guide clinical and regulatory policies, as they will help us understand the magnitude of the potential risk of retention and juxtapose this to the benefits to help determine when or if risks of retention outweigh benefits. Such a model should be generated for each approved GBCA.
Variables available to these models may be limited for some GBCAs that have less market penetration or more limited clinical use. Risk models might be different for different populations, such as children. Note.-See Table E2 (online) for complete roadmap table. ADME = absorption, distribution, metabolism, and excretion; CSF = cerebrospinal fluid; GBCA = gadolinium-based contrast agent; ICP-MS = inductively coupled plasma mass-spectrometry; NSF = nephrogenic systemic fibrosis; XRF = x-ray fluorescence.
immunologic effect of gadolinium exposure and symptoms, immunologists might provide useful insights. Finally, toxicologists with expertise in low-concentration population exposure of a potentially toxic substance should be consulted to better inform these research efforts.
Knowledge Gaps and Prioritized Research Roadmap
Given the importance of the subject matter and the clinical utility of GBCAs, it is important not only to identify the knowledge gaps in this area, but also to guide collaborative research. The participants in the workshop formulated a roadmap to help guide future animal (Table 3, Table E1 [online]) and clinical (Table 4, Table E2 [online]) studies. Standardization and validation of gadolinium and GBCA tissue measurement methods and quality assurance procedures is crucial to these efforts.
Conclusion
The greatest priority for the research roadmap is to understand if gadolinium retention is causally associated with clinical manifestations, as this knowledge will help direct and define the urgency of subsequent research efforts. In spite of more than 30 years of use of GBCAs, important information about the biodistribution and tissue interactions of each GBCA in clinical use remains unknown. It is clear that gadolinium retention in a number of tissues, including bone, skin, and brain, beyond 24 hours may occur with all types of GBCAs, although the magnitude of observed retention is greater with linear GBCAs than with macrocyclic GBCAs. The observed signal intensity changes in the brain account for only some of the retained gadolinium in the brain and other tissues. The research needed must include consideration of the importance of shorter-term retention (<1 month) and longer-term retention in different organs.
Not yet known is the extent, mechanism, chemical form, and clinical implications of chronic gadolinium retention for each GBCA in the general population and in vulnerable populations, such as children and those with relevant comorbidities that may be at higher risk for potential retention. These unknowns call for more systematic research and form the basis of this research roadmap to improve our understanding of gadolinium retention and its clinical importance.
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